858 Therapeutics Stock Price, Funding, Valuation, …

Jul 11, 2024 · See 858 Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on 858 Therapeutics's post-money valuation and revenue. ... Funding, Valuation & Revenue. 4 Fundings. 858 Therapeutics has raised $110M over 4 …

CouponFollow Extension

$110
OFF

858 Therapeutics Stock Price, Funding, Valuation, …

6 days from now

cbinsights.com

$2
OFF

858 Therapeutics: Revenue, Competitors, Alternatives

6 days from now

858 Therapeutics top competitors are DiaCarta, Mission Bio and Quadrants Scientific and they have annual revenue of $2.6M and 34 employees. ... Estimated Revenue & Valuation. 858 …

growjo.com

$78
OFF

858 Therapeutics - Company Profile - Tracxn

6 days from now

Nov 1, 2024 · 858 Therapeutics ranks 364th among 2371 active competitors. 857 of its competitors are funded while 543 have exited. Overall, 858 Therapeutics and its competitors have raised over $78.9B in funding across 3345 funding rounds involving 7782 investors. There are 4 private unicorns, 358 public and 185 acquired companies in the entire competition set.

tracxn.com

$50
OFF

858 Therapeutics Raises $50 Million In Series B Funding To …

6 days from now

Sep 26, 2024 · 858 Therapeutics has secured $50 million in a Series B funding round led by Avidity Partners, with participation from Insight Partners, Mirae Asset Capital, and Alexandria Venture Investments. Existing investors Versant Ventures, NEA, and Logos Capital also contributed. This financing will fuel the advancement of 858 Therapeutics’ pipeline of small …

siliconvalleyjournals.com

$50
OFF

858 Therapeutics Nabs $50M Round - San Diego Business …

6 days from now

Oct 14, 2024 · LA JOLLA– Torrey Pines-based 858 Therapeutics has successfully raised $50 million in Series B financing to advance its pipeline of small molecule drugs that target cancer …

sdbj.com

$60
OFF

Calling San Diego: 858 Therapeutics Closes $60M Series A …

6 days from now

Sep 21, 2021 · 858 Therapeutics Inc. emerged from stealth mode, unveiling $60 million in series A funding and plans to drug a series of protein targets involved in modulating RNA biology in …

bioworld.com

$80.06
OFF

858 Therapeutics Company Profile - Office Locations ... - Craft

6 days from now

858 Therapeutics has 1 employees at their 1 location and $80.06 m in total funding,. See insights on 858 Therapeutics including office locations, competitors, revenue, financials, executives, …

craft.co

$60
OFF

858 Therapeutics Raises $60 Million - Chemical

6 days from now

Sep 24, 2021 · 858 Therapeutics has launched with $60 million in series A financing to develop small-molecule cancer drugs. The San Diego-based start-up also acquired Gotham …

acs.org

$60
OFF

858 Therapeutics Launches With $60 Million Series A

6 days from now

Sep 23, 2021 · The funding will enrich 858’s discovery platform by interrogating a novel area – RNA therapeutics to treat patients with intractable forms of cancer. “The launch of 858 builds …

geneonline.com

$60
OFF

858 Therapeutics Launches With $60 Million And Acquisition …

6 days from now

Sep 20, 2021 · After operating for more than 2 years in stealth, the biotech startup 858 Therapeutics has formally launched with $60 million in series A financing to develop small …

acs.org

FAQs about 858 Therapeutics Stock Price, Funding, Valuation, … Coupon?

What happened to 858 Therapeutics?

SAN DIEGO-- ( BUSINESS WIRE )--858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital. ...

Where is 858 Therapeutics headquarters?

Where is 858 Therapeutics 's headquarters? 858 Therapeutics is located in San Diego, California, United States. Who invested in 858 Therapeutics? 858 Therapeutics has 4 investors including New Enterprise Associates and Cormorant Asset Management. ...

Why did 858 acquire Gotham Therapeutics?

To accelerate the development of its pipeline, 858 has acquired Gotham Therapeutics for undisclosed terms. Gotham is a pioneer in the field of RNA biology, translating novel biological discoveries from the lab of Samie Jaffrey, M.D., Ph.D., co-founder of Gotham and now an advisor to 858. ...

Will funding help 858's METTL3 program in 2023?

The financing for 858 Therapeutics should help advance their lead programs, including the METTL3 program from Gotham, into the clinic by 2023.\nStafford says... Gotham was based on the work of its cofounder Samie Jaffrey, a scientist at Weill Cornell Medicine. Jaffrey is now an advisor to 858. ...

Who are the founders of 858?

858’s founding team includes CEO Jeffrey Stafford, Ph.D., CSO James Veal, Ph.D., and VP of Biology Gretchen Bain, Ph.D. They previously held leadership roles at three other San Diego-based discovery companies co-founded by Versant including Jecure Therapeutics, Quanticel Pharmaceuticals and Amira Pharmaceuticals. ...

What does 858 do?

858 has built a platform to assess the impact of RNA-modifying proteins on disease biology and has generated a pipeline of small molecules against priority targets. The platform includes a suite of proprietary in vitro biochemical and biophysical assays, as well as cellular assays. ...